-+ 0.00%
-+ 0.00%
-+ 0.00%

CEL-SCI’s Investigational Cancer Immunotherapy Multikine Granted Official Designation Under Saudi Food And Drug Authority’s New Accelerator Program For Drugs In Rare Diseases

Benzinga·11/20/2026 13:04:15
Listen to the news
  • Establishes 160-working-day Saudi FDA (SFDA) priority review target following marketing authorization submission, accelerating Multikine’s potential Saudi commercial market entry to 2027 or early 2028
  • Commercialization partnership with Amarox provides fully funded in-country distribution and a 50/50 revenue share while building localized biopharma capabilities
  • Saudi FDA’s New Accelerator Program for Drugs in Rare Diseases (NADR) grants priority access and scientific flexibility, advancing Saudi Vision 2030 healthcare initiatives

CEL-SCI Corporation (NYSE:CVM) today announced that its investigational cancer immunotherapy Multikine® (Leukocyte Interleukin, Injection) has been granted official designation under the Saudi Food and Drug Authority’s (SFDA) New Accelerator Program for Drugs in Rare Diseases (NADR). The designation application was successfully submitted by Amarox, CEL-SCI’s in-country regulatory and commercialization partner in Saudi Arabia.

The NADR designation positions Saudi Arabia to potentially become the first commercial market globally for Multikine®. With NADR status secured, CEL-SCI and Amarox are preparing to submit a Marketing Authorization Application (MAA) to the SFDA within the next 2-3 months. Under recently enacted SFDA guidance, products designated under the NADR pathway qualify for priority review with a target assessment timeframe of 160 working days, supporting a potential commercial launch and initial commercial sales of Multikine in 2027 or early 2028, pending SFDA approval and review of the MAA.